Evidence map›Paper›PMID 38698259›Full record

ArticleSurgical endoscopy2024

Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study.

Enpan Xu, Qiang Shi, Zhipeng Qi, Bing Li, Huihui Sun, Zhong Ren, Shilun Cai, Dongli He, Zhengtao Lv, Zhanghan Chen and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Enpan XuZhongshan Hospital, Fudan University, Shanghai, China.
Qiang ShiZhongshan Hospital, Fudan University, Shanghai, China.
Zhipeng QiZhongshan Hospital, Fudan University, Shanghai, China.
Bing LiZhongshan Hospital, Fudan University, Shanghai, China.
Huihui SunTongji Hospital Affiliated to Tongji University, Shanghai Tongji Hospital, Shanghai, China.
Zhong RenZhongshan Hospital, Fudan University, Shanghai, China.
Shilun CaiZhongshan Hospital, Fudan University, Shanghai, China.
Dongli HeShanghai Xuhui Central Hospital, Fudan University, Shanghai, China.
Zhengtao LvZhongshan Hospital, Fudan University, Shanghai, China.
Zhanghan ChenZhongshan Hospital, Fudan University, Shanghai, China.
Liang ZhongHuashan Hospital, Fudan University, Shanghai, China.
Leiming XuXinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China.
Xiaobo LiShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Shuchang XuTongji Hospital Affiliated to Tongji University, Shanghai Tongji Hospital, Shanghai, China.
Pinghong ZhouZhongshan Hospital, Fudan University, Shanghai, China.
Yunshi ZhongZhongshan Hospital, Fudan University, Shanghai, China. zhong.yunshi@zs-hospital.sh.cn.ORCID 0000-0002-3128-3168

Funding

Shanghai Municipal Commission of Science and Technology 19411951600Shanghai Municipal Commission of Science and Technology 22S31903800
6 · The paper itself

Abstract

BACKGROUND AND

aimsMany studies of gastric gastrointestinal stromal tumors (g-GISTs) following endoscopic resection (ER) have typically focused on tumor size, with most tumors at low risk of aggressiveness after risk stratification. There have been few systematic studies on the oncologic outcomes of intermediate- or high-risk g-GISTs after ER.

methodsFrom January 2014 to January 2020, we retrospectively collected patients considered at intermediate- or high-risk of g-GISTs according to the modified NIH consensus classification system. The primary outcome was overall survival (OS).

resultsSix hundred and seventy nine (679) consecutive patients were diagnosed with g-GISTs and treated by ER between January 2014 and January 2020 in three hospitals in Shanghai, China. 43 patients (20 males and 23 females) were confirmed at intermediate-or high-risk. The mean size of tumors was 2.23 ± 1.01 cm. The median follow-up period was 62.02 ± 15.34 months, with a range of 28 to 105 months. There were no recurrences or metastases, even among patients having R1 resections. The 5-year OS rate was 97.4% (42/43).

conclusionER for intermediate- or high-risk gastric small GISTs is a feasible and safe method, which allows for a wait-and-see approach before determining the necessity for imatinib adjuvant or surgical treatment. This approach to g-GISTs does require that patients undergo close follow-up.

Indexed as

Gastrointestinal Stromal TumorsStomach NeoplasmsAdultAgedAged, 80 and overChinaFemaleGastrectomyGastroscopyHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeEndoscopic resectiong-GISTsHigh-riskIntermediate-risk

Identifiers

PMID38698259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.